secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001213900-24-013637
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helix Acquisition Corp. II closes $184M IPO, including full over-allotment
--------------------------------------------------------------------------

- Closed IPO of 18.4M Class A shares at $10.00 each; gross proceeds $184M.
- Underwriter exercised over-allotment option in full for additional 2.4M shares.
- Sponsor purchased 509,000 private placement shares at $10.00 for $5.09M.
- Total $184M placed in trust; must complete business combination within 24 months.
- Appointed Mark C. McKenna and John Schmid as independent directors; charter amended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/0001213900-24-013637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000121390024013637/ea193423-8k_helixacq2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-013637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer